Vapotherm Inc
F:VA21
Vapotherm Inc
Depreciation & Amortization
Vapotherm Inc
Depreciation & Amortization Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Depreciation & Amortization | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
V
|
Vapotherm Inc
F:VA21
|
Depreciation & Amortization
$5m
|
CAGR 3-Years
1%
|
CAGR 5-Years
18%
|
CAGR 10-Years
N/A
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Depreciation & Amortization
$1.4B
|
CAGR 3-Years
6%
|
CAGR 5-Years
4%
|
CAGR 10-Years
6%
|
|
|
Stryker Corp
NYSE:SYK
|
Depreciation & Amortization
$1.2B
|
CAGR 3-Years
6%
|
CAGR 5-Years
8%
|
CAGR 10-Years
12%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Depreciation & Amortization
$3.1B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
8%
|
|
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
Depreciation & Amortization
$145.2m
|
CAGR 3-Years
9%
|
CAGR 5-Years
9%
|
CAGR 10-Years
8%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Depreciation & Amortization
$677.1m
|
CAGR 3-Years
20%
|
CAGR 5-Years
18%
|
CAGR 10-Years
22%
|
|
Vapotherm Inc
Glance View
Vapotherm, Inc. is a medical technology company, which engages in the development and commercialization of medical devices for patients suffering from respiratory distress. The company is headquartered in Exeter, New Hampshire and currently employs 510 full-time employees. The company went IPO on 2018-11-14. The firm is focused on the care of patients of all ages suffering from the respiratory distress often associated with complex lung diseases, such as chronic obstructive pulmonary disease (COPD), congestive heart failure (CHF), pneumonia, asthma and COVID-19. Its device solutions are focused on high velocity nasal insufflation (HVNI), which delivers non-invasive ventilatory support to patients suffering from respiratory distress. Its HVNI technology delivers heated, humidified and oxygenated air at a high velocity through a small-bore nasal interface. The company offers four versions of its Precision Flow systems, which includes Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic and Precision Flow Heliox. Its Precision Flow systems include a capital unit, a single-use disposable and a nasal interface. Its digital solutions are focused on at home patient monitoring. The firm also provides various clinical solutions.
See Also
What is Vapotherm Inc's Depreciation & Amortization?
Depreciation & Amortization
5m
USD
Based on the financial report for Dec 31, 2023, Vapotherm Inc's Depreciation & Amortization amounts to 5m USD.
What is Vapotherm Inc's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 5Y
18%
Over the last year, the Depreciation & Amortization growth was -4%. The average annual Depreciation & Amortization growth rates for Vapotherm Inc have been 1% over the past three years , 18% over the past five years .
